

# Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: a cross-sectional study

Anastase Dzudie,<sup>1,2</sup> André Pascal Kengne,<sup>3</sup> Walinjom F T Muna,<sup>4,5</sup> Hamadou Ba,<sup>5</sup> Alain Menanga,<sup>4,5</sup> Charles Kouam Kouam,<sup>6</sup> Joseph Abah,<sup>7</sup> Yves Monkam,<sup>1</sup> Christian Biholong,<sup>1</sup> Pierre Mintom,<sup>5</sup> Félicité Kamdem,<sup>1</sup> Armel Djomou,<sup>1</sup> Jules Ndjebet,<sup>1</sup> Cyrille Wambo,<sup>1</sup> Henry Luma,<sup>1</sup> Kathleen Blackett Ngu,<sup>8</sup> Samuel Kingue,<sup>4,5</sup> On behalf of the CCS investigator group<sup>i</sup>

**To cite:** Dzudie A, Kengne AP, Muna WFT, *et al*. Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: a cross-sectional study. *BMJ Open* 2012;**0**:e001217. doi:10.1136/bmjopen-2012-001217

► Prepublication history and additional material for this paper are available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2012-001217>).

For author footnote see end of the article.

Received 1 April 2012  
Accepted 23 July 2012

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see <http://bmjopen.bmj.com>

For numbered affiliations see end of article

**Correspondence to**  
Dr Anastase Dzudie;  
[aitdzudie@yahoo.com](mailto:aitdzudie@yahoo.com)

## ABSTRACT

**Objectives:** Hypertension has been established as a major public health problem in Africa, but its specific contributions to disease burden are still incompletely understood. We report the prevalence and determinants of hypertension, detection, treatment and control rates among adults in major cities in Cameroon.

**Design:** Cross-sectional study.

**Settings:** Community-based multicentre study in major cities in Cameroon.

**Participants:** Participants were self-selected urban dwellers from the Center, Littoral, North-West and West Regions, who attended on 17 May 2011 a screening campaign advertised through mass media.

**Primary and secondary outcomes measures:** Hypertension defined as systolic (and/or diastolic) blood pressure (BP)  $\geq$  140 (90) mm Hg, or ongoing BP-lowering medications.

**Results:** In all, 2120 participants (1003 women) were included. Among them, 1007 (prevalence rate 47.5%) had hypertension, including 319 (awareness rate 31.7%) who were aware of their status. The prevalence of hypertension increased with age overall and by sex and region. Among aware hypertensive participants, 191 (treatment rate 59.9%) were on regular BP-lowering medication, and among those treated, 47 (controlled rate 24.6%) were at target BP levels (ie, systolic (and diastolic) BP < 140 (90) mm Hg). In multivariable logistic regression analysis, male gender, advanced age, parental history of hypertension, diabetes mellitus, elevated waist and elevated body mass index (BMI) were the significant predictors of hypertension. Likewise, male gender, high BMI and physical inactivity were associated with poor control.

**Conclusions:** High prevalence of hypertension with low awareness, treatment and control were found in this urban population; these findings are significant and alarming with consideration to the various improvements in the access to healthcare and the continuing efforts to educate communities over the last few decades.

## ARTICLE SUMMARY

### Article focus

► This article quantified the burden and determinants of hypertension, detection, treatment and control rates among self-selected adults in major cities in Cameroon, central Africa.

### Key messages

► The prevalence of hypertension was very high in this population, coupled with low detection, treatment and control rates.  
► Age, gender and excess weight were the main drivers of the high prevalence, while the coincidence of classical cardiovascular risk factors was associated with poor control.

### Strengths and limitations of this study

► Major strengths of this study include the large sample, the multicenter nature, the rigorous data collection on a range of determinants and provision of standardised prevalence figures.  
► Limitations include the selection of participants, and hypertension diagnosis based on blood pressure measurement during a single encounter.

## INTRODUCTION

Hypertension has been established as a major public health problem worldwide.<sup>1</sup> Several published studies suggest that hypertension is the commonest modifiable risk factor for stroke, congestive heart failure and kidney failure<sup>2–5</sup> in the sub-Saharan African (SSA) region. It is a major contributor to overall death risk in adults in the region.<sup>6</sup> Hypertension also seems to be more common in urban than rural population<sup>7</sup> of the SSA region.

## Prevalence, awareness, treatment and control of hypertension

Specific risks associated with various blood pressure (BP) readings have largely been established for populations in many parts of the developed world but this is not the case for countries of the developing world including the SSA region. There is considerable evidence that long-term BP lowering to what is considered either normal or optimal levels results in several significant and important health benefits.<sup>8</sup> When established norms for ideal or optimal BP are applied to SSA populations, it becomes very evident that the vast majority of eligible patients do not enjoy the benefits of BP-lowering therapies, either because of under-diagnosis or the many other barriers to BP-lowering medications prescription, access and compliance in this setting.<sup>1 2</sup> As a case-in point, a survey in Cameroon about 8 years ago found that only 23% of all individuals with hypertension at the community level were aware of their status.<sup>9</sup> Moreover, only 46% of those aware (11% of all those with hypertension) were on treatment, among whom only 19% (2% of all those with hypertension) achieved expected target BP levels.<sup>9</sup>

There is also evidence that SSA is undergoing very rapid transitions characterised by increasing urbanisation, including the adoption of unhealthy lifestyles.<sup>10 11</sup> These transitions are paralleled by changes in the profile of chronic disease risk factors including BP.<sup>7</sup> Recently, there has been increasing awareness of the threat that the looming chronic diseases pose to the health of the population in the Region at different levels.<sup>12</sup> This increasing awareness has catalysed initiatives aimed at improving access to detection and care of chronic diseases including hypertension<sup>13</sup> in many countries of the region. The pace of the above mutations suggests that data on the burden of hypertension must be updated regularly, in order to provide the reliability needed in drawing-up health service and policy solutions.

The aim of this study was to assess the prevalence and determinants of hypertension, and including the detection, treatment and control rates, as well as the variability by region and gender in four major cities of Cameroon.

### MATERIAL AND METHODS

#### Study population and settings

This was a cross-sectional population-based study conducted in the regional capitals of the Centre (Yaounde), Littoral (Douala), North-West (Bamenda) and West (Bafoussam) administrative regions (out of a total of 10) of Cameroon. According to the Cameroon National Institute of Statistics,<sup>14</sup> the four participating regions had a total population of 9.98 million in 2010 (51% of the country's total population: 19.41 millions). In the same year, 57.5% of the national population was aged 15 years and above, and about 52% resided in what was defined as an urban area.<sup>14</sup> During three consecutive weeks leading to the specified day of the survey, daily

announcements were made through radio and television, inviting all interested adults (or individuals aged 15 years and above) to report to any of the screening sites in participating cities. Such explanation included advice on the importance of measuring and knowing one's BP under the slogan 'I know my BP. And you?'. Announcements were also made in churches and market places. The study protocol was approved by the Cameroon National Ethics Committee and signed informed consent was obtained from each participant.

#### Data collection

The screening was conducted by trained medical personnel, simultaneously in the four cities on the specified date of 17 May 2011. All participants were subjected to a face-to-face interview during which data were collected (using a standardised questionnaire) on demographics, smoking habits and alcohol consumption, physical activity, parental history of hypertension, personal medical history (where the diagnosis was made by a physician) of hypertension including drug treatment, diabetes mellitus, gout and dyslipidaemia. The physical examination included BP and anthropometric measurements. BP (systolic and diastolic) was measured using a standardised protocol with the participant in a seated position, and after at least 10 min rest. Participants with evidence of recent (less than 30 min) alcohol intake or smoking were invited to a 30 min rest before BP measurement. BP measurements were performed on the right arm using automated sphygmomanometers (OMRON M3 HEM-7200-E Omron Matsusaka Co Ltd, Kyoto, Japan). Special attention was given to the use of appropriate cuff sizes (13×23 cm or 16×30 cm). Weight (to the nearest 0.5 kg) was measured with the use of an automated scale. Participants were permitted to keep on light clothing. Height (in metres to the nearest 0.5 cm) was measured using a wooden platform and a height rule. Body mass index (BMI in kg/m<sup>2</sup>) was calculated as weight (kg)/(height (m)×height (m)). Waist circumference was measured midway between the iliac crest and the lower rib margin and the hip circumference was measured at the intertrochanteric level. Waist-to-hip ratio (WHR) was calculated as waist (cm)/hip (cm) circumferences.

#### Definitions

Respondents were classified as hypertensive if they had a systolic (and/or diastolic) BP of 140 (90) mm Hg or higher, or if they were on BP-lowering medications over the last 15 consecutive days. Participants with hypertension were considered to be aware of their status if they answered 'yes' to the question 'Have you ever been told by a doctor or health professional that you had hypertension?'. Treatment of high BP was defined by the use of BP-lowering medications. Hypertension was considered to be controlled among treated individuals when systolic (and diastolic) SBP was <140 (90) mm Hg or <130 (80) mm Hg in individuals with diabetes. Waist

circumference >94 cm in men or 80 cm in women was considered to be high. Excessive alcohol consumption was based on intake of either more than 3 (2 for women) standard glasses of wine per day or more than 10 (5 for women) local beers (1 local beer contains 28 g of alcohol) per week. Traditional alcohol beverages were not assessed. Participants who smoked at least one cigarette per day at the time of the study were classified as current smokers, and those who have smoked for at least 3 years in the past, but had stopped by the time of the study, were classified as former smokers. Regular non-work-related physical activity was considered in participants reporting at least 30 min of intense physical activity, once a week or more.

### Handling of participants with high BP

Participants with hypertension (known or screened-detected) received on-site medical counseling and were referred back to their attending physician (known cases), or to specialists within the vicinity of the participant's residential area for workup and long-term management. Few participants with excessively high BP with or without suspected acute target organ damage were immediately referred to emergency departments for appropriate care.

### Statistical analysis

Data analysis used the Statistical Package for Social Sciences (SPSS Inc, Chicago, Illinois, USA) V.17.0 software. Results are summarised as count and percentages for qualitative variables and mean and SD for quantitative variables. Age-adjusted prevalence was calculated using the Cameroon National population's age structure in 2010 as standard population.<sup>15</sup> Direct standardisation methods was applied.<sup>16</sup> Group comparisons used  $\chi^2$  tests and equivalents for qualitative variables and student t test, analysis of the variance for quantitative variables. Logistic regression analyses were used to investigate potential determinants of prevalent hypertension and control. A p value <0.05 was used to characterise statistically significant results.

### Sensitivity analysis

The main analyses were based on a single BP measurement. To assess the potential effects of 'regression to the mean' phenomenon on the prevalence of hypertension, a sensitivity analysis was conducted among participants with a raised initial BP (SBP/DBP $\geq$ 140/80 mm Hg) and who had their BP taken a second time on the same day. This analysis was based on the average of the first and second measurements.

## RESULTS

### Study population

About 2120 eligible participants reported for screening in the four regions including 649 (30.6%) in the Centre, 1167 (54.1%) in the Littoral and 304 (14.3%) in the

West and North West regions. Their overall profile including gender and region is summarised in [table 1](#). Participants included 1003 women (47.3%). Compared with men, women had similar age (43 vs 44 years,  $p=0.19$ ), similar waist circumference (93 vs 93 cm,  $p=0.80$ ) and similar history of diabetes mellitus, dyslipidaemia and gout (all  $p\geq 0.07$ , [table 1](#)). They were likely to have higher BMI, higher prevalence of parental history of hypertension, lower systolic and diastolic BP, and were less likely to be either a smoker or alcohol drinker and physically active (all  $p\leq 0.001$ , [table 1](#)). With a few exceptions, the above pattern was consistent within participating regions. However, the small number of recruits in some subgroups translated into non-significant men/women differences ([table 1](#)). With the exception of smoking ( $p=0.07$ ), differences were also apparent in the baseline profile across Regions (all  $p\leq 0.01$  for differences across regions; [table 1](#)).

### BP profile

Mean systolic and diastolic BP (SD) at the total population level (men vs women) was 139 (25) vs 134 (28) mm Hg ( $p<0.001$ ), and 83 (17) vs 80 (17) mm Hg ( $p=0.001$ ). Mean systolic BP steadily increased with increasing age in men and women and across participating regions. Diastolic BP also increased with increasing age, but only up to the fourth and fifth decade of age, after which the pressure stabilised. This was observed in men and women and across regions ([figure 1](#)).

The distribution of participants by BP categories according to the 2003 ESH/ESC classification<sup>17</sup> was examined by sex and regions, overall and by age groups. An optimal BP (systolic BP<120 and diastolic BP<80 mm Hg) was observed in 21.6% of men and 29.6% of women. The prevalence of optimal or normal BP decreased with increasing age in men and women (all  $p\leq 0.001$  for linear trend). Conversely, with the exception of grade 1 hypertension (both  $p\geq 0.09$  for linearity) and high normal BP in women only ( $p=0.13$ ), the prevalence of all other BP categories linearly increased with increasing age (all  $p<0.001$  for linear trend). Similar trends were also observed across participating regions. However, the distribution of participants across BP categories varied significantly by region ( $p<0.0001$ ).

### Prevalence of hypertension and awareness and control rates

The prevalence of hypertension was 47.5% overall, and 50.1% and 44.6% in men and women, respectively ( $p<0.001$ , [table 2](#)). As expected, prevalence rate sharply increased with age down from 31.7% (men) and 20.2% (women) in the age group <35 years, up to 77.6% (men) and 75.2% (women) in the age group 55 years and above ([table 2](#)). Awareness rate increased with increasing age in men and women (both  $p<0.001$  for linear trend). Among participants with hypertension, 24.6% in men and 40.5% in women were aware of their condition, and those remaining were newly diagnosed.

## Prevalence, awareness, treatment and control of hypertension

**Table 1** General characteristics of the study population overall and by region

Characteristic	Regions											
	Centre			Littoral			North-West and West			Overall		
	Men	Women	p	Men	Women	p	Men	Women	p	Men	Women	p
N	376	273		609	558		132	172		1117	1003	
Mean age, years (SD)	41 (12)	42 (14)	0.43	45 (13)	43 (14)	0.33	48 (14)	45 (14)	0.08	44 (13)	43 (14)	0.19
Age groups, n (years)			0.26			0.006			0.22			0.01
<35	134	97		145	180		23	44		302	321	
35–44	99	57		154	108		32	40		285	205	
45–54	86	65		163	139		34	47		284	251	
≥55	57	54		146	131		43	41		246	226	
Mean BMI, kg/m <sup>2</sup> (SD)	26.2 (4)	27.2 (4.5)	0.002	26.9 (4.8)	29 (6.3)	<0.001	27.6 (5)	29.3 (5.4)	0.006	26.7 (4.6)	28.6 (5.8)	<0.001
Waist girth, cm (SD)	96 (13)	94 (12)	0.04	91 (13)	91 (15)	0.31	95 (12)	97 (12)	0.15	93 (13)	93 (14)	0.80
Mean SBP, mm Hg (SD)	133 (22)	129 (24)	0.06	142 (26)	139 (30)	0.05	136 (25)	125 (25)	<0.001	139 (25)	134 (28)	<0.001
Mean DBP, mm Hg (SD)	77 (17)	77 (16)	0.98	85 (17)	82 (18)	0.001	85 (15)	79 (15)	0.001	83 (17)	80 (17)	0.001
Parental hypertension, n	77	77	0.02	158	191	0.002	38	55	0.62	273	323	<0.001
History of diabetes, n	27	27	0.22	27	31	0.42	21	31	0.65	75	89	0.07
History of dyslipidaemia, n	1	0	>0.99	4	9	0.16	0	0	N/A	5	9	0.28
History of gout, n	0	1	0.42	13	9	0.53	1	0	0.43	14	10	0.68
Physical activity, n	160	86	0.004	334	180	<0.001	82	104	0.77	576	370	<0.001
Smoking, n			<0.001			<0.001			<0.001			<0.001
Never	320	267		500	540		113	170		933	977	
Former	21	26		43	7		4	0		68	12	
Current	35	36		66	11		15	2		116	14	
Excessive alcohol, n	85	17	<0.001	147	51	<0.001	51	32	<0.001	283	100	<0.001

BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.

## Prevalence, awareness, treatment and control of hypertension

**Table 2** Hypertension prevalence, awareness and control among self-selected urban dwellers in Cameroon


Gender region	Variable	Overall	Overall*	Age groups (years)				p Trend
				<35	35–44	45–54	≥55	
Centre	Prevalence (%)	35.4	27.3 (23.3–31.3)	15.1	28.2	48.3	70.3	<0.001
	SBP/DBP $\geq$ 140/90 mm Hg or treatment (n)	230	230	35	44	73	78	
	Awareness (%)	30.4	12.5 (9.3–15.7)	0	22.7	31.5	47.4	<0.001
	Among hypertensives (n)	70	70	0	10	23	37	
	Treatment (%)	61.4	21.9 (13.6–30.2)	NA	50	52.2	70.3	0.13
	Among aware hypertensives (n)	43	43	NA	5	12	26	
	Control A (%)	25.6	6.7 (2.5–10.9)	NA	0	33.3	26.9	0.41
	Among treated hypertensive (n)	11	11	NA	0	4	7	
Littoral	Prevalence (%)	53.6	43.6 (39.2–48)	33.8	45	61.7	76.2	<0.001
	SBP/DBP $\geq$ 140/90 mm Hg or treatment (n)	626	626	110	118	187	211	
	Awareness (%)	25.1	15.1 (11.3–18.9)	9.1	11.9	25.1	40.8	<0.001
	Among hypertensives (n)	157	157	10	14	47	86	
	Treatment (%)	49	38.7 (16.7–60.7)	30	57.1	46.8	51.2	0.42
	Among aware hypertensives (n)	77	77	3	8	22	44	
	Control A (%)	18.2	26.8 (–13.7 to 67.3)	33.3	12.5	22.7	15.9	0.60
	Among treated hypertensive (n)	14	14	1	1	5	7	
Others	Prevalence (%)	49.7	34.4 (26.6–42.2)	22.4	30.6	51.8	85.7	<0.001
	SBP/DBP $\geq$ 140/90 mm Hg or treatment (n)	151	151	15	22	42	72	
	Awareness (%)	60.9	30.3 (17.7–42.9)	13.3	40.9	53.5	77.8	<0.001
	Among hypertensives (n)	92	92	2	9	25	56	
	Treatment (%)	77.7	91.6 (5.6–178)	100	77.8	84	73.2	0.30
	Among aware hypertensives (n)	71	71	2	7	21	41	
	Control A (%)	31	12.9 (4.7–21.1)	0	42.9	14.3	39	0.22
	Among treated hypertensive (n)	22	22	0	3	3	16	
Men	Prevalence (%)	50.1	41.3 (36.9–45.7)	31.7	38.9	57.2	77.6	<0.001
	SBP/DBP $\geq$ 140/90 mm Hg or treatment (n)	560	560	96	111	162	191	
	Awareness (%)	24.6	13.5 (10–17)	6.3	12.6	21.6	43.5	<0.001
	Among hypertensives (n)	138	138	6	14	35	83	
	Treatment (%)	57.9	54.6 (19.3–89.9)	50	64.2	65.7	54.2	0.53
	Among aware hypertensives (n)	80	80	3	9	23	45	
	Control A (%)	18.8	28.2 (–12 to 68.6)	33.3	22.2	21.7	15.5	0.36
	Among treated hypertensive (n)	15	15	1	2	5	7	
Women	Prevalence (%)	44.6	32.5 (28.8–36.2)	20.2	35.6	55.8	75.2	<0.001
	SBP/DBP $\geq$ 140/90 mm Hg or treatment (n)	447	447	64	73	140	170	
	Awareness (%)	40.5	20.9 (15.6–26.2)	9.3	26	42.8	54.5	<0.001
	Among hypertensives (n)	181	181	6	19	60	96	
	Treatment (%)	61.3	43.3 (13.9–72.7)	33.3	57.9	53.3	68.9	0.03
	Among aware hypertensives (n)	111	111	2	11	32	66	
	Control A (%)	28.8	8 (4.6–13.8)	0	18.1	21.8	34.8	0.08
	Among treated hypertensive (n)	32	32	0	2	7	23	
	Control B (%)	38.7	12.8 (7.2–18.4)	0	2.7	31.3	45.5	0.06
	Among treated hypertensive (n)	43	43	0	3	10	30	

Data are percentages with numerators below. Control A, blood pressure below 140/90 mm Hg or 130/80 mm Hg among diabetic patients; Control B, blood pressure below 140/90 mm Hg among all participants.

\*Age standardized according to the 2010 Cameroon national population distribution.

DBP, diastolic blood pressure; NA, not applicable; SBP, systolic blood pressure.

## Prevalence, awareness, treatment and control of hypertension



**Figure 1** Mean systolic and diastolic blood pressure by age groups for men (left panel) and women (right panel).

Of those aware of their hypertensive status, 57.9% in men and 61.3% in women were on BP-lowering medications, similarly across age groups in men ( $p=0.53$  for linear trend), and with a modest linearly increasing trend with age in women ( $p=0.03$ , [table 2](#)). Among treated patients, 27.5% in men and 38.7% in women were at target BP levels (ie, systolic (and diastolic) BP<140 (90) mm Hg), and similarly across age strata (both  $p\geq 0.06$  for linear trend). Control rate was about 10% lower when the target BP level of <130 (80) was applied to participants with diabetes ([table 2](#)).

Crude prevalence of hypertension, awareness and treatment varied significantly across participating regions (all  $p<0.001$ ). The highest crude prevalence (53.6%) was observed in the Littoral region, while the highest crude awareness (60.9%) and treatment rates (49%) were observed in provinces other than Centre and Littoral ([table 2](#)). Control rate was also higher in those two regions when the threshold level of 140/90 mm Hg was applied to all treatment participants ( $p<0.001$ ). This difference, however, was non-significant when the threshold of 130/80 mm Hg was applied to participants with diabetes. The age trends in prevalence, awareness, treatment and control across regions were largely similar to those observed in men and women ([table 2](#)).

### Predictors of hypertension and control among urban dwellers

Unadjusted and adjusted ORs and 95% CIs for the association of prevalent hypertension with potential predictors are shown in [table 3](#). In multivariable logistic regression models adjusted for age, sex, parental history of hypertension, BMI and region, the significant predictors of prevalent hypertension were male sex, increasing age, region, parental history of hypertension, personal history of diabetes, high BMI and high waist circumference ([table 3](#)). In multivariable models with similar level of adjustment ([table 4](#)), male sex, high BMI and physical

inactivity were associated with poor control of hypertension, while being from Regions other than Centre or Littoral was associated with good control among treated patients ([table 4](#)).

### Sensitivity analysis

Among participants with newly diagnosed hypertension based on the first BP measurement (688 participants), 537 (78%) had a valid second measurement. Their mean BP (SD) was 159.4 (19) for systolic and 94.4 (14.2) mm Hg for diastolic based on the first measurement. Equivalent values were 154.5 (19) and 93 (13.1) mm Hg based on the average of the two measurements. Of the 537 participants, 461 (85.8%) had hypertension (systolic/diastolic BP $\geq$ 140/90 mm Hg) using the average of the two BP measurements.

### DISCUSSION

In this self-selected urban adult population study from Cameroon, we found a high prevalence of hypertension, coupled with low detection, treatment and control rates. The high prevalence was largely driven by age, as well as by gender and excess weight. However, among those diagnosed and on treatment, control rate was similar across age groups, although there were suggestions of regional differences, possibly reflecting underlying differences in the access to healthcare and health resources utilisation. Our study provides comparative data across major cities in Cameroon and suggests findings compatible with previously reported high prevalence rates of hypertension in the country.

### Prevalence of hypertension

During the last 10 years, at least two prevalence studies on hypertension have been reported in urban Cameroon, applying similar definitions for hypertension, but different sampling strategies.<sup>7 9 18</sup> The age-adjusted prevalence of hypertension in the current study is

## Prevalence, awareness, treatment and control of hypertension

**Table 3** Crude and adjusted ORs for predictors of hypertension among self-selected urban dwellers in Cameroon

Variable	Category	Unadjusted ORs (95% CI)	p	Adjusted ORs (95% CI)*	p
Sex	Men	1.25 (1.05 to 1.48)	0.01	1.63 (1.34 to 2)	<0.001
Age (years)	<35	1 (reference)	<0.001	1 (reference)	<0.001
	35–44	1.74 (1.35 to 2.25)		1.32 (1.01 to 1.73)	
	45–54	3.75 (2.93 to 4.81)		2.81 (2.16 to 3.64)	
	≥55	9.41 (7.12 to 12.43)		8.27 (6.19 to 11.04)	
Region	Centre	1 (reference)	<0.001	1 (reference)	<0.001
	Littoral	2.11 (1.73 to 2.57)		1.89 (1.52 to 2.36)	
	Others	1.80 (1.36 to 2.37)		1.38 (1.01 to 1.89)	
Parental hypertension	Yes	1.47 (1.21 to 1.77)	<0.001	1.55 (1.25 to 1.92)	<0.001
Diabetes mellitus	Yes	3.77 (2.61 to 5.44)	<0.001	2.63 (1.75 to 3.94)	<0.001
Dyslipidemia	Yes	2 (0.67 to 5.98)	0.22	1.55 (0.47 to 5.11)	0.47
Gout	Yes	3.36 (1.33 to 8.49)	0.01	1.70 (0.62 to 4.67)	0.30
Smoking	Never	1 (reference)	0.11	1 (reference)	0.62
	Former	1.59 (1.01 to 2.51)		0.96 (0.59 to 1.65)	
	Current	0.90 (0.63 to 1.29)		0.82 (0.54 to 1.22)	
Physical activity	No	0.90 (0.76 to 1.07)	0.23	1.13 (0.93 to 1.38)	0.21
Excessive alcohol	Yes	1.33 (1.06 to 1.66)	0.01	1.05 (0.81 to 1.36)	0.70
Body mass index	Normal	1 (reference)	<0.001	1 (reference)	<0.001
	Overweight	2.03 (1.65 to 2.50)		1.94 (1.54 to 2.45)	
	Obese	3.54 (2.83 to 4.43)		3.32 (2.57 to 4.29)	
High waist girth		2.12 (1.78 to 2.52)	<0.001	1.94 (1.51 to 2.48)	<0.001

\*Age, sex, parental history of hypertension, body mass index and region adjusted.

higher than that reported by Kamadjeu<sup>9</sup> in 2003, but similar to the findings of Fezeu<sup>7</sup> around that same time. This balance of findings would tend to suggest that the prevalence of hypertension in this setting is either stabilising or growing at a much slower pace than previously reported.<sup>7</sup>

Elsewhere, available data on hypertension in Africa are from very heterogeneous studies, and therefore offer less opportunities for reliable comparison.<sup>3</sup> Such heterogeneities include differences in sampling methods and study settings (predominance of hospital-based study), the type of participants enrolled, the measurements of

**Table 4** Crude and adjusted ORs for predictors of hypertension control among self-selected and treated hypertensives in four main cities of Cameroon

Variable	Category (%)	Unadjusted ORs (95% CI)	p	Adjusted ORs (95% CI)*	p
Sex	Men	0.59 (0.35 to 1)	0.05	0.47 (0.26 to 0.86)	0.01
Age (years)	<35	1 (reference)	0.87	1 (reference)	0.63
	35–44	0.54 (0.12 to 2.32)		0.38 (0.07 to 1.99)	
	45–54	0.68 (0.19 to 2.45)		0.57 (0.13 to 2.41)	
	≥55	0.67 (0.19 to 2.34)		0.46 (0.11 to 1.88)	
Region	Centre	1 (reference)	<0.001	1 (reference)	<0.001
	Littoral	0.72 (0.35 to 1.50)		0.70 (0.33 to 1.52)	
	Others	3.36 (1.64 to 6.87)		3.50 (1.65 to 7.42)	
Parental hypertension	Yes	1.44 (0.87 to 2.40)	0.16	1.56 (0.89 to 2.75)	
Diabetes mellitus	Yes	2.73 (1.60 to 4.67)	<0.001	1.83 (0.98 to 3.39)	0.06
Dyslipidemia	Yes	0.74 (0.08 to 6.75)	0.79	1.30 (0.13 to 13.26)	0.83
Gout	Yes	NA (none)			
Smoking	Never	1 (reference)	0.53	1 (reference)	0.72
	Former	0.79 (0.21 to 2.89)		1.26 (0.30 to 5.34)	
	Current	0.32 (0.04 to 2.57)		0.44 (0.05 to 3.97)	
Physical activity	No	0.30 (0.17 to 0.56)	<0.001	0.36 (0.20 to 0.66)	0.001
Excessive alcohol	Yes	0.59 (0.26 to 1.32)	0.20	0.64 (0.26 to 1.60)	0.34
Body mass index	Normal	1 (reference)	0.002	1 (reference)	0.003
	Overweight	0.41 (0.22 to 0.77)		0.44 (0.22 to 0.90)	
	Obese	0.34 (0.18 to 0.66)		0.28 (0.14 to 0.59)	
High waist girth		0.86 (0.51 to 1.44)	0.56	0.77 (0.33 to 1.77)	0.54

\*Age, sex, parental history of hypertension, body mass index and region adjusted.

## Prevalence, awareness, treatment and control of hypertension

BP and definition of hypertension and the time period when the study was conducted.<sup>19</sup> Reliable, large-scale, population-based data on high BP in SSA are very limited; however, available recent studies provide findings that demonstrate similarly high prevalence of hypertension in urban settings.<sup>20–22</sup> Moreover, those findings already tend to be similar to those reported in the developed world,<sup>23–24</sup> therefore, raising serious concerns given the young age of clinical onset of hypertension in Africa.

### Awareness, treatment and control of hypertension

In Cameroon, over the last 10 years, there have been a number of initiatives aimed at scaling up the fight against chronic diseases in general, and hypertension and diabetes mellitus in particular,<sup>25</sup> including: (1) the adoption of a National Strategy for hypertension and diabetes<sup>25</sup> and (2) the development of training and task-shifting programmes to improve detection and management at the primary care level.<sup>13–26</sup> Findings from our study would tend to suggest that the good will contained in the National Strategy has perhaps not yet been fully translated into actions with sizable positive effects on the health of the population. For instance, the strategy aimed to improve the level of risk factors by 25% and achieve optimal control among those diagnosed with the condition.<sup>25</sup> However, we found awareness, treatment and control rates that were within the range of those previously reported in Cameroon prior to the adoption of the strategy<sup>7–9</sup> and recently in other settings in Africa.<sup>20–22–25</sup> The low awareness rate, if confirmed, could be blamed on low-detection activity and accordingly non-optimal performance of the National strategy. It is also possible that many participants already diagnosed with hypertension, and perhaps on treatment and controlled on such treatment, did not feel the need to attend the screening campaign again. This would have the undesirable effect of biasing our estimates by providing much lower than the true figures. It is also possible that those with known and treated condition instead turned out in higher number to use the campaign as an opportunity for their health check-up free of charge. Our stratified analyses suggest that this mix could vary substantially by participating centres. In general, however, low awareness of hypertension has been reported as a global phenomenon,<sup>27</sup> although the magnitude may be less important in the developed world.<sup>23–28</sup> In the USA, for instance, awareness of hypertension is as high as 76%,<sup>28</sup> reflecting the success achieved by a coordinated policy to detect individuals with higher-than-optimal BP levels.

The low treatment and control rates in our study reflect the interplay between many factors that were not directly captured by the current study. These include patient-level, healthcare provider level and health system-level factors. Indeed, patients are expected to be treated and controlled only if they can access appropriate health services, receive adequate advice and

prescriptions and subsequently afford and adhere to those prescriptions. Accessibility to healthcare facility has likely improved in urban settings in Cameroon in recent years. However, the physician-to-population ratio, just like in many other countries in the region, is still very low<sup>29</sup> and may explain the low awareness and treatment gaps. Affordability of the cost of care also remains a major barrier in the study setting where out-of-pocket spending is the main source of funding for healthcare costs. Adherence to prescribed medications is another patient-level determinant of risk factor control not investigated in the present study. Studies in Africa have shown that non-adherence to treatment and follow-up for hypertension was very common.<sup>30–32</sup> In one intervention study in Cameroon, for instance, just about half of the participants were still in the programme at 1-year follow-up.<sup>31</sup>

### Potential limitations and strengths of our study

The present study has some limitations. Participants were self-selected and may therefore not necessarily be representative of the general population in participating cities. Access to mass media (radio and television) is almost universal in major cities in the countries, and there is therefore no suggestion that advertisement of the campaign would have selectively reached certain portions of the population. It remains, however, that participants in the study could still differ from the general population by being more or less health conscious, and having less severe disease, for example, which could affect some parameters in the study. The study used a cross-sectional design, which precludes any causality inference. Diagnosis of hypertension was based on BP measurements during a single encounter, which is at variant with guidelines recommendations for hypertension diagnosis using two measurements recorded on three separate occasions.<sup>17</sup> This may have overestimated the prevalence of hypertension and underestimated the level of BP control. This, however, would not affect comparisons with previous epidemiological studies that have used similar measurement methodology. Diagnosis of hypertension among those with no history of hypertension in our study was based on a single BP measurement. Our sensitivity analysis suggests that this approach could inflate the crude prevalence by about 5.4% and 4.6% among those not known to have hypertension prior to the survey and at the total population level, respectively. Nevertheless, even after accounting for this possible effect, our estimates would still be within sampling variation of the figures previously reported in this setting. It is also of note that no participant received a definitive diagnosis of hypertension as a result of taking part in this study. Those with elevated BP levels were instead referred to healthcare facilities for further evaluation. The strengths of this study include the large sample of the general population and the rigorous collection of various lifestyle factors, medical data and BP measurements by trained staff according to standardised



protocols, the adequate standardisation of prevalence and allowing comparisons with other African countries. In addition, our sampling approach provides evidence that simple announcements through mass media can attract from the community a large number of individual at risk of undiagnosed hypertension.

## Conclusions

In conclusion, our study has provided findings that are in line with the high prevalence of hypertension previously reported in urban settings in Africa. The study also suggests that efforts to detect and treat to the targets those with the disease are still below optimal. This raises serious concerns about the prospects of having to care very soon for both patients with higher-than-optimal BP and many more with target organ lesions subsequent to longstanding hypertension. There are already some indications that the burden of stroke, end-stage renal disease and heart failure related to hypertension is growing in the country and the region.<sup>2 6 33</sup>

## PERSPECTIVES

The low awareness, treatment and control rates of hypertension in this potentially health conscious urban sub-Saharan population invite innovative approaches to improve prevention, detection, treatment of hypertension beyond the traditional healthcare facilities-based approaches that are currently in force in many countries in the region.

### Author affiliations

<sup>1</sup>Department of Internal Medicine, Douala General Hospital, Douala, Cameroon

<sup>2</sup>Department of Internal Medicine, Faculty of Health Sciences, University of Buea, Buea, Cameroon

<sup>3</sup>NCRP or Cardiovascular and Metabolic Disease, South African Medical Research Council & University of Cape Town, Cape Town, South Africa

<sup>4</sup>Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, Yaounde, Cameroon

<sup>5</sup>Department of Internal Medicine, Yaounde General Hospital, Douala, Cameroon

<sup>6</sup>Department of Internal Medicine, Bafoussam Regional Hospital, Douala, Cameroon

<sup>7</sup>Department of Internal Medicine, Bamenda Military Hospital, North West Region, Cameroon

<sup>8</sup>Department of Internal Medicine, Yaounde University Teaching Hospital, Yaounde, Cameroon

### Author footnote

Members list in the appendix section.

**Acknowledgements** The authors would like to express their gratitude to the following bodies and individuals for their contribution to the success of this study: (1) The Cameroon Ministry of public health for providing the blood pressure devices and health staff; (2) The executive committee and members of the Cameroon Cardiac Society for their support for data collection; (3) Servier Pharma Cameroon for a financial contribution to support data processing and drafting of the manuscript; (4) All specialist physicians, enthusiastic general practitioners, medical students and nurses involved in data collection and (5) All those who helped at different stages of the project and the fellow Cameroonians who volunteered across the four participating cities to take part in the study.

**Contributors** AD and APK had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data

analysis. Study concept and design by AD, APK, WFTM, KBN and SK. Acquisition of data by HB, AM, CKK, JA, YM, CB, PM, FK, AD, JN, CO, HL. Analysis and interpretation by AD, APK and WFTM. Drafting of the manuscript by AD, APK and WFTM. Critical revision of the manuscript for important intellectual content by all coauthors.

**Competing interest** None.

**Ethics approval** Cameroon National Ethics Committee.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data available.

## REFERENCES

1. Kearney PM, Whelton M, Reynolds K, *et al.* Global burden of hypertension: analysis of worldwide data. *Lancet* 2005;365:217–23.
2. Kengne AP, Anderson CS. The neglected burden of stroke in sub-Saharan Africa. *Int J Stroke* 2006;1:180–90.
3. Addo J, Smeeth L, Leon DA. Hypertension in sub-Saharan Africa: a systematic review. *Hypertension* 2007;50:1012–18.
4. Kengne AP, Amoah AG, Mbanya JC. Cardiovascular complications of diabetes mellitus in sub-Saharan Africa. *Circulation* 2005;112:3592–601.
5. Damasceno A, Cotter G, Dzudie A, *et al.* Heart failure in sub-Saharan Africa: time for action. *J Am Coll Cardiol* 2007;50:1688–93.
6. Kengne AP, Awah PK. Classical cardiovascular risk factors and all-cause mortality in rural Cameroon. *QJM* 2009;102:209–15.
7. Fezeu L, Kengne AP, Balkau B, *et al.* Ten-year change in blood pressure levels and prevalence of hypertension in urban and rural Cameroon. *J Epidemiol Community Health* 2010;64:360–5.
8. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 2003;362:1527–35.
9. Kamadjeu RM, Edwards R, Atanga JS, *et al.* Prevalence, awareness and management of hypertension in Cameroon: findings of the 2003 Cameroon Burden of Diabetes Baseline Survey. *J Hum Hypertens* 2006;20:91–2.
10. Leon DA. Cities, urbanization and health. *Int J Epidemiol* 2008;37:4–8.
11. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases. *Am J Clin Nutr* 2006;84:289–98.
12. de-Graft Aikins A, Unwin N, Agyemang C, *et al.* Tackling Africa's chronic disease burden: from the local to the global. *Glob Health* 2010;6:5.
13. Lekoubou A, Awah P, Fezeu L, *et al.* Hypertension, diabetes mellitus and task shifting in their management in sub-Saharan Africa. *Int J Environ Res Public Health* 2010;7:353–63.
14. Cameroon's National Institute of Statistics. *Statistical year book 2010*. Chapter 4: Characteristics of the population 2011:39–52. Available at [www.statistics-cameroon.org/downloads/annuaire2010/chap4.pdf](http://www.statistics-cameroon.org/downloads/annuaire2010/chap4.pdf). Accessed on 11/12/2011.
15. Cameroon's National Institute of Statistics. *Population du Cameroun en 2010*. 2011. Available at [www.statistics-cameroon.org/downloads/La\\_population\\_du\\_Cameroun\\_2010.pdf](http://www.statistics-cameroon.org/downloads/La_population_du_Cameroun_2010.pdf). Accessed on 15/11/2011.
16. Woodward M, ed. *Epidemiology: study design and data analysis*. 2nd edn. New York: Chapman & Hall/CRC, 2005.
17. Mancia G, De Backer G, Dominiczak A, *et al.* 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007;25:1105–87.
18. Kengne AP, Awah KP, Fezeu L, *et al.* The burden of high blood pressure and related risk factors in urban sub-Saharan Africa: evidences from Douala in Cameroon. *Afr Health Sci* 2007;7:38–44.
19. Danaei G, Finucane MM, Lin JK, *et al.* National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. *Lancet* 2011;377:568–77.
20. Jenson A, Omar AL, Omar MA, *et al.* Assessment of hypertension control in a district of Mombasa, Kenya. *Glob Public Health* 2011;6:293–306.
21. Ulasi II, Ijoma CK, Onodugo OD. A community-based study of hypertension and cardio-metabolic syndrome in semi-urban and rural communities in Nigeria. *BMC Health Serv Res* 2010;10:71.
22. Damasceno A, Azevedo A, Silva-Matos C, *et al.* Hypertension prevalence, awareness, treatment, and control in mozambique:

## Prevalence, awareness, treatment and control of hypertension

- urban/rural gap during epidemiological transition. *Hypertension* 2009;54:77–83.
23. Wagner A, Sadoun A, Dallongeville J, *et al*. High blood pressure prevalence and control in a middle-aged French population and their associated factors: the MONA LISA study. *J Hypertens* 2011;29:43–50.
  24. Wolf-Maier K, Cooper RS, Banegas JR, *et al*. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *JAMA* 2003;289:2363–9.
  25. Njamnshi AK, Bella Hiag A, Mbanya JC. From research to policy: the development of a national diabetes programme in Cameroon. *Diabetes Voice* 2006;55:18–21.
  26. Kengne AP, Sobngwi E, Fezeu L, *et al*. Setting-up nurse-led pilot clinics for the management of non-communicable diseases at primary health care level in resource-limited settings of Africa. *PAMJ* 2009;3:10.
  27. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? *J Hum Hypertens* 1997;11:213–20.
  28. Cheung BM, Ong KL, Man YB, *et al*. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. *J Clin Hypertens (Greenwich)* 2006;8:93–8.
  29. World Health Organisation. *Task shifting to tackle health worker shortage*, WHO, Geneva, 2007.
  30. Kengne AP, Awah PK, Fezeu LL, *et al*. Primary health care for hypertension by nurses in rural and urban sub-Saharan Africa. *J Clin Hypertens (Greenwich)* 2009;11:564–72.
  31. Labhardt ND, Balo JR, Ndam M, *et al*. Improved retention rates with low-cost interventions in hypertension and diabetes management in a rural African environment of nurse-led care: a cluster-randomised trial. *Trop Med Int Health* 2011. doi: 10.1111/j.1365-3156.2011.02827.x. [Epub ahead of print]
  32. Dennison CR, Peer N, Steyn K, *et al*. Determinants of hypertension care and control among peri-urban Black South Africans: the HiHi study. *Ethn Dis* 2007;17:484–91.
  33. Halle MP, Kengne AP, Ashuntantang G. Referral of patients with kidney impairment for specialist care in a developing country of sub-Saharan Africa. *Ren Fail* 2009;31:341–8.

### APPENDIX 1

#### Cameroon Cardiac Society (CCS) investigators group

1. Douala: Anastase Dzudie, Hamadou Ba, Henri Roger Ngote, Christian Biholong, Félicité Kamdem, Armel Djomou, Jules Njebet, Cyrille Wambo, Roger Mboulley Kotto, Barbara Bouellet Abeng, Marielle Epacka Ewane Lobe and Yves Monkam.
2. Yaounde: Alain Menanga, Pierre Mintom, Euloge Yiagnigni, Méricée Ouankou, Christophe Nouedoui, Pierre Ndobu, Marie Ntep, Monique Kenfack, Sylvie Ndongo, Martine Tchuem, Edvine Wawo, Walinjom F.T. Muna, Kathleen Ngu Blackett and Samuel Kingue.
3. Bafoussam: Charles Kouam Kouam
4. Bamenda: Joseph Abah.

**BMJ Open**

## Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: a cross-sectional study

Anastase Dzudie, André Pascal Kengne, Walinjom F T Muna, et al.

*BMJ Open* 2012 2:

doi: [10.1136/bmjopen-2012-001217](https://doi.org/10.1136/bmjopen-2012-001217)

---

Updated information and services can be found at:

<http://bmjopen.bmj.com/content/2/4/e001217.full.html>

---

*These include:*

### References

This article cites 28 articles, 7 of which can be accessed free at:

<http://bmjopen.bmj.com/content/2/4/e001217.full.html#ref-list-1>

Article cited in:

<http://bmjopen.bmj.com/content/2/4/e001217.full.html#related-urls>

### Open Access

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See:

<http://creativecommons.org/licenses/by-nc/3.0/> and

<http://creativecommons.org/licenses/by-nc/3.0/legalcode>.

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Topic Collections

Articles on similar topics can be found in the following collections

[Cardiovascular medicine](#) (279 articles)

[Epidemiology](#) (700 articles)

[Global health](#) (141 articles)

---

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>

## Notes

---

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>